Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...
Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback